Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/5943
Title: | Does the prognosis of nasopharyngeal cancer differ among endemic and non-endemic regions? | Authors: | Demirci, Senem Kamer, S. Kara, G. Yıldırım, Özgür Esassolak, M. |
Keywords: | Chemoradiotherapy Radiotherapy Treatment outcome amifostine bleomycin cisplatin cortisone docetaxel epirubicin hydroxyurea UFT adolescent adult aged article brain necrosis cancer chemotherapy cancer classification cancer radiotherapy cancer recurrence clinical feature controlled study cranial nerve cranial nerve paralysis disease free survival distant metastasis eye disease female follow up headache human inner ear disease lethargy major clinical study male medical literature medical record review multiple cycle treatment multivariate analysis nasopharynx cancer overall survival paralysis priority journal prognosis retrospective study salivary gland disease seizure skin toxicity spinal cord disease survival rate temporal lobe necrosis treatment outcome treatment response trismus xerostomia Adolescent Adult Aged Aged, 80 and over Combined Modality Therapy Disease-Free Survival Endemic Diseases Female Follow-Up Studies Humans Incidence Male Middle Aged Nasopharyngeal Neoplasms Neoplasm Recurrence, Local Prognosis Retrospective Studies Survival Rate Turkey Young Adult |
Abstract: | Conclusion: The survival rates and prognostic factors for nasopharyngeal cancer (NPC) were found to be similar to the published series from endemic regions. Objectives: The purpose of this retrospective study was to evaluate treatment outcome and prognostic factors of NPC patients treated with radiotherapy or chemoradiotherapy in a non-endemic region. Methods: We analyzed clinical characteristics, treatment outcome, and prognostic factors of NPC patients in a non-endemic region, and compared our institution's results with the published literature including a similar patient population from endemic and non-endemic regions. Among 248 NPC patients, 71 (28.6%) were female and 177 (71.4%) were male with a median age of 48 years. Results: Within a median 59 months (range 22178) of follow-up, local recurrence developed in 22 (8.9%), regional recurrence in 2 (0.8%), locoregional recurrence in 5 (2%), distant metastases in 21 (8.5%), and both locoregional recurrence and distant metastases in 8 (3.2%) patients. Five-year locoregional control (LRC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS) rates were 83.7%, 73%, 78.5%, and 71.1%, respectively. In multivariate analysis for LRC, cranial nerve involvement (CNI) (p = 0.009) and tumor response (p = 0.004); for DFS, age (p = 0.003), CNI (p = 0.02), AJCC T classification (p = 0.05), and tumor response (p = 0.01); for DSS, age (p = 0.003), CNI (p = 0.04), AJCC T classification (p = 0.04), and tumor response (p = 0.01); for OS, age (p < 0.001), AJCC T classification (p = 0.005), and tumor response (p < 0.001) were significant prognostic factors. © 2011 Informa Healthcare. | URI: | https://hdl.handle.net/11499/5943 https://doi.org/10.3109/00016489.2011.560188 |
ISSN: | 0001-6489 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
6
checked on May 11, 2025
WEB OF SCIENCETM
Citations
3
checked on May 13, 2025
Page view(s)
96
checked on May 11, 2025
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.